Curis Gets FDA Acceptance of Application to Initiate Skin Cancer Trial

Curis has announced that an investigational new drug (IND) application filed by its collaborator Genentech has been accepted by the FDA.

This acceptance provides approval for Genentech to initiate a Phase I clinical trial of a drug candidate for the topical treatment of basal cell carcinoma.

This drug candidate is an antagonist of the Hedgehog signaling pathway that was discovered by Curis and is being co-developed through a collaboration between Genentech and Curis.